Skip navigation |

Study: Sofosbuvir plus Ledipasvir against HCV Geno 1

It seems like the inclusion of another HCV direct-acting antiviral (DAA) to existing DAA therapy can overcome the limitations of interferon-free and ribavirin-free therapies used to treat the most difficult to treat patients with hepatitis C. Although relatively small, this study produced very high cure rates across all of the patient groups who received the triple combination DAA therapy regardless of existing poor predictors of treatment response. — Alan Franciscus HCV Advocate

Gastroenterology. 2013 Nov 18. pii: S0016-5085(13)01653-3. doi: 10.1053/j.gastro.2013.11.007.

Abstract:

BACKGROUND & AIMS:
We evaluated an all-oral regimen comprising sofosbuvir with ledipasvir or GS-9669 in patients with genotype 1 hepatitis C virus infection.

METHODS:
A total of 113 patients were enrolled. The primary efficacy endpoint was sustained virologic response 12 weeks after therapy (SVR12).

  • Sofosbuvir (400 mg once daily) and ledipasvir (90 mg once daily) plus ribavirin were given for 12 weeks to treatment-naïve patients (n=25) and those who did not respond to previous therapy (prior null responders, n=9).
  • Sofosbuvir and GS-9669 (500 mg once daily) plus ribavirin were given for 12 weeks to treatment-naïve patients (n=25) and prior null responders (n=10).
  • Additionally, prior null responders with cirrhosis were randomly assigned to groups given a fixed-dose combination of sofosbuvir and ledipasvir, with ribavirin (n=9) or without ribavirin (n=10).
  • Finally, a group of treatment-naïve patients received sofosbuvir, ledipasvir, and ribavirin for 6 weeks (n=25).

RESULTS:
SVR12 was achieved by 25/25 (100%) of treatment-naïve patients receiving sofosbuvir, ledipasvir, and ribavirin and 23/25 (92%) of those receiving sofosbuvir, GS-9669, and ribavirin.

Of treatment-naïve patients receiving 6 weeks of sofosbuvir, ledipasvir, and ribavirin, 17/25 (68%) achieved SVR12.

All non-cirrhotic prior null responders receiving 12 weeks of sofosbuvir along with another direct-acting antiviral agent plus ribavirin achieved SVR12 - 9/9 (100%) of those receiving sofosbuvir, ledipasvir, and ribavirin and 10/10 (100%) of those receiving sofosbuvir, GS-9669, and ribavirin.

Among cirrhotic prior null responders, SVR12 was achieved by 9 (100%) of those receiving sofosbuvir, ledipasvir, and ribavirin and 7 (70%) of those receiving sofosbuvir and ledipasvir without ribavirin. The most common reported adverse events were headache, fatigue, and nausea.

CONCLUSIONS:
The combination of sofosbuvir and a second direct-acting antiviral agent is highly effective in treatment-naïve patients with HCV genotype 1 infection and in patients that did not respond to previous treatment.

CLINICALTRIALS.GOV NUMBER:NCT01260350.

Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Source: New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New ealand edgane@adhb.govt.nz